News & Updates

Consumption of alcohol appears to be a risk factor for early-onset colorectal cancer and has driven an increase in the incidence of colorectal cancer among young adults, as shown in a study.

Next-generation sequencing (NGS)–based analysis of circulating tumour DNA (ctDNA) helps predict benefit of second-line (2L) ripretinib or sunitinib therapy in patients with imatinib-resistant advanced gastrointestinal stromal tumours (GIST), an exploratory subanalysis of the INTRIGUE trial has shown.

Individuals who received radiation therapy for Hodgkin's lymphoma are at increased risk of colorectal cancer, as reported in a study.

A combination regimen comprising zolbetuximab and mFOLFOX6* chemotherapy (CT) regimen showed potential as first-line treatment for claudin-18.2-positive**/HER2-negative (CLDN18.2+/HER2–) locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, according to the primary findings of the phase III SPOTLIGHT trial.

Hormone therapy drugs, such as bicalutamide, flutamide, nilutamide, goserelin, degarelix, and apalutamide, appear to increase the likelihood of developing interstitial lung disease (ILD) events in patients with prostate cancer, reports a study.

The addition of bevacizumab (BVZ) to the standard regimen for the treatment of advanced colorectal cancer (CRC) appears to increase the risk of cardiovascular events, suggest the results of a meta-analysis presented at the recent ASCO Gastrointestinal Cancers Symposium (ASCO GI 2023).